Leading & informing a growing landscape.

Numinus Wellness looking to position itself at the forefront of psychedelics for healing and wellness

Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms. Click here to read more.

Numinus Wellness's trial for MDMA-assisted therapy is in pre-implementation stage

The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned…

Numinus Wellness (NUMI.V) lab services agreement with Optimi Health puts them out front in functional mushroom market

Numinus Wellness (NUMI.V) entered into a lab services agreement with Optimi Health to develop a functional mushroom brand for the health and wellness sector earlier this week, according to a press…

Numinus Execs: No Quick Pathway for Psychedelics

Our founders Payton Nyquvest and Stacey Wallin sat down with Investing News Network to talk about how Numinus is setting the table for psychedelic therapy and what investors should expect as the…

Psychedelics in Therapy

Numinus Chief Medical Officer Dr. Evan Wood and CEO Payton Nyquvest were invited to speak with Simon Fraser University's Stu McNish for the Conversations That Matter program. Click here to watch the…

Stacey Wallin & Payton Nyquvest - Waking up to a new consciousness

Payton Nyquvest and Stacey Wallin join Paul Austin to discuss their new project, Numinus, a company at the forefront of transformative changes in treating mental illness, addictions, trauma while…